Company intelligence / Profile preview

Modern Mournin

Cambridge, Massachusetts, United Statesmlb.com ↗

Ownership: Private
Employees: ~5800
Development stage: Other

Overview

Moderna has two approved commercial products—SPIKEVAX® (COVID‑19 vaccine) and mRESVIA® (RSV vaccine)—and over three dozen clinical-stage candidates targeting infectious diseases, rare diseases, and cancer. Its personalized cancer vaccine candidate with Merck received FDA breakthrough status in early trials.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsVaccineMonoclonal antibody (encoded by mRNA)Small moleculeProtein therapy
Industry: Biotech

Partnerships

Merck & Co.Biomedical Advanced Research and Development Authority (BARDA)Bill & Melinda Gates FoundationChinese government collaboration on China-only drugsBenchling partnership for R&D informaticsMultiplex contract manufacturing partner in Australia

Beyond the preview

Go deeper on Modern Mournin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modern Mournin.

Explore the full profile